VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 27
- +1 vs. Q4 2021
- Portfolio value
- $617.2M
- −$114.3M (−15.6%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SVRASavara Inc | COM | 1,905,265 | $2.50M | 0.4% | +1,905,265 | New | History |
| JBIOJade Biosciences, Inc. | COM | 151,037 | $2.77M | 0.4% | +151,037 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 538,999 | $3.62M | 0.6% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 411,361 | $3.69M | 0.6% | −715,911−63.5% | Reduced | History |
| ALTAltimmune, Inc. | COM NEW | 759,719 | $4.63M | 0.7% | +759,719 | New | History |
| SRRASierra Oncology, Inc. | COM NEW | 162,479 | $5.21M | 0.8% | +162,479 | New | History |
| Affimed N VN01045108 | COM | 1,428,571 | $6.24M | 1.0% | 00.0% | Unchanged | – |
| ATYRaTYR PHARMA INC | COM NEW | 1,398,889 | $7.48M | 1.2% | −166,111−10.6% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 1,088,817 | $8.15M | 1.3% | 00.0% | Unchanged | History |
| PRVBProvention Bio, Inc. | COM | 1,118,653 | $8.19M | 1.3% | +1,118,653 | New | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,612,617 | $8.22M | 1.3% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 803,951 | $11.2M | 1.8% | 00.0% | Unchanged | History |
| EIGREiger BioPharmaceuticals, Inc. | COM | 1,469,767 | $12.2M | 2.0% | +1,469,767 | New | History |
| LONALeonaBio, Inc. | COM | 1,000,000 | $13.5M | 2.2% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 16,047,286 | $19.9M | 3.2% | 00.0% | Unchanged | History |
| LIANYLianBio | SPONSORED ADS | 5,378,341 | $20.0M | 3.2% | 00.0% | Unchanged | History |
| KDNYChinook Therapeutics, Inc. | COM | 1,283,821 | $21.0M | 3.4% | 00.0% | Unchanged | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 1,529,402 | $26.0M | 4.2% | 00.0% | Unchanged | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 865,116 | $29.5M | 4.8% | 00.0% | Unchanged | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 3,156,803 | $29.5M | 4.8% | +276,707+9.6% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,852,919 | $34.3M | 5.6% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 4,494,851 | $36.9M | 6.0% | +1,000,000+28.6% | Added | History |
| GHRSGH Research PLC | ORDINARY SHARES | 2,051,060 | $37.5M | 6.1% | +29,075+1.4% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,994,997 | $51.4M | 8.3% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 2,270,072 | $61.3M | 9.9% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 6,865,076 | $73.8M | 12.0% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $78.7M | 12.7% | 00.0% | Unchanged | History |
Sold out since Q4 2021 (5)
Positions held at the end of Q4 2021 that are gone from this filing.
| Security | Class | Shares in Q4 2021 | Value in Q4 2021 | % of portfolio in Q4 2021 | History |
|---|---|---|---|---|---|
| KNTEKinnate Biopharma Inc. | COM | 773,014 | $13.7M | 1.9% | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 816,651 | $7.64M | 1.0% | History |
| CVRXCVRx, Inc. | COM | 533,370 | $6.52M | 0.9% | History |
| AKYAAkoya Biosciences, Inc. | COM | 400,000 | $6.12M | 0.8% | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 250,000 | $603.0K | 0.1% | History |